In acute myeloid leukemia (AML), GLUT3 negatively regulates epidermal growth factor receptor (EGFR) activity and its downstream signaling pathways, contributing to tyrosine kinase inhibitors (TKIs) chemoresistance (Zhuang et al. 2018). This evidence concerns the gene SLC2A3 and acute myeloid leukemia.